Navigation

Head and neck cancer - contusugene ladenovec [ID76]

Contusugene ladenovec within its licensed indication for the treatment of unresectable recurrent and/or refractory squamous cell carcinoma of the head and neck

Status: Suspended
Expected date of issue: TBC
Referral date: March 2009
Process: STA
Notes:

Cancer reform strategy Batch 3

Topic area:
  • Cancer
 

NICE project team

Executive Lead: TBC
Technical Lead: TBC
Communications manager: TBC
Project manager: Jeremy Powell
Top


 

Provisional schedule

Closing date for invited submissions / evidence submission: TBC
1st appraisal committee meeting: TBC
Top


 

Consultees and commentators

To be confirmed

Top


 

Project history

Date Update
14 August 2009 Appraisal suspended
Top


 

Key documents

This page was last updated: 04 July 2012

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.